Personalised pharmacometabolomic optimisation of treatment for hypertension (HYPERMARKER)

高血压，或称高血压，是一种严重的疾病，也是导致循环系统疾病的最大因素，循环系统疾病仍然是欧盟各地死亡和发病的主要原因。它几乎占所有医疗保健相关成本的10%。收缩期高血压导致各种各样的疾病，对患者和医疗保健系统都有巨大的影响。HYPERMARKER将释放药物代谢组学的潜力，提供抗高血压治疗的“聪明”处方。来自11个欧洲国家的表型良好的队列将提供代谢组谱和血液样本，用于药物代谢学评估，以使用先进的人工智能和深度学习方法确定高血压治疗反应的预测因素。抗高血压药物对个体治疗反应的预测模型将通过欧洲4个地点的创新随机对照试验进行临床验证和改进。其结果是一种临床决策支持工具，将使临床医生能够在知情的情况下选择他们正在治疗的患者是否对血管紧张素抑制药、钙拮抗剂、β受体阻滞剂或一系列其他现有药物的使用做出最佳反应，这些药物具有循证控制血压的作用。为了确保可持续性，该项目还将制定一个框架，以便在欧洲及其他地区为高血压患者提供常规护理时采用这一工具。HYPERMARKER将由一群来自不同学科的世界级科学家和临床医生实施，他们曾多次合作，并拥有领先的国家和欧盟资助的关键倡议的记录，以交付高影响力的成果。

Hypertension, or high blood pressure (BP), is a serious medical condition, and the single biggest contributor to circulatory diseases which continue to dominate as the leading cause of death and morbidity across the EU. It accounts for almost 10 percent of all healthcare-related costs. Systolic hypertension leads to a broad variety of diseases with an immense impact on both patients and healthcare systems. HYPERMARKER will unleash the potential of pharmacometabolomics to provide a ‘smart’ prescription of antihypertensive therapy. Well-phenotyped cohortsfrom eleven European countries will provide metabolomic profiles and blood samples for pharmacometabolomic assessments to identify predictors of treatment response in hypertension using advanced AI and deep learning methods. Prediction models for individual treatment responses to antihypertensive medication will be clinically validated and refined through an innovative RCT across 4 sites in Europe. The result is a clinical decision support tool that will give clinicians the ability to make an informed selection of whether the patient they are treating will best respond to the use of angiotensin inhibition, calcium antagonists, beta-blockers, or a range of other existing drugs with evidence-based for BP control. To ensure sustainability, the project will also develop a framework for the uptake of this tool in routine care for patients with hypertension across Europe and beyond. HYPERMARKER will be implemented by a group of world-class scientists and clinicians from a diversity of disciplines who have collaborated multiple times and have a track record of leading key national and EU-funded initiatives to deliver high-impact results.